Drug Profile
GW 501516
Alternative Names: 501516; GSK-516; GW-501516; GW-516Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Ligand Pharmaceuticals
- Developer GlaxoSmithKline
- Class Antihyperlipidaemics; Small molecules; Thiazoles
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 21 Dec 2005 Data presented at the 78th Scientific Sessions of the American Heart Association (AHA-2005) have been added to the Hyperlipidaemia pharmacodynamics section
- 10 Dec 2003 Phase-II clinical trials in Hyperlipidaemia in USA (unspecified route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline